Published in Transplantation on May 15, 2002
Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant (2010) 0.90
New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs (2014) 0.84
Current state of renal transplant immunosuppression: Present and future. World J Transplant (2012) 0.81
Adding thymoglobuline to the conventional immunosuppressant regimen in kidney transplantation: A cost-benefit analysis. Caspian J Intern Med (2012) 0.81
Induction Therapy in Renal Transplantation: Why? What Agent? What Dose? We May Never Know. Clin J Am Soc Nephrol (2015) 0.80
Review on immunosuppression in liver transplantation. World J Hepatol (2015) 0.79
Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation. Transpl Int (2013) 0.78
Biologics in renal transplantation. Pediatr Nephrol (2014) 0.75
The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep (2015) 0.75
A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition. Transplant Direct (2016) 0.75
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. J Transplant (2012) 0.75
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
How deceased donor transplantation is impacting a decline in commercial transplantation-the Tamil Nadu experience. Transplantation (2012) 2.14
Donors with central nervous system malignancies: are they truly safe? Transplantation (2003) 2.12
Malignancy after transplantation. Transplantation (2005) 1.92
Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. Clin J Am Soc Nephrol (2010) 1.75
A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg (2008) 1.74
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Comparing living donor and deceased donor liver transplantation: A matched national analysis from 2007 to 2012. Liver Transpl (2014) 1.63
Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. Kidney Int (2012) 1.58
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Severe venous neointimal hyperplasia prior to dialysis access surgery. Nephrol Dial Transplant (2011) 1.54
Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis (2009) 1.52
One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant (2007) 1.51
Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem (2008) 1.48
Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation (2008) 1.46
Hand-assisted laparoscopic living-donor nephrectomy as an alternative to traditional laparoscopic living-donor nephrectomy. Am J Transplant (2002) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Temporary silastic mesh closure for adult liver transplantation: a safe alternative for the difficult abdomen. Liver Transpl (2007) 1.40
Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol (2005) 1.32
An initial experience and evolution of laparoscopic hepatic resectional surgery. Surgery (2004) 1.26
De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation (2009) 1.25
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation (2010) 1.25
Venous stenosis in a pig arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant (2007) 1.22
West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation (2004) 1.18
Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. Kidney Int (2002) 1.12
Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int (2012) 1.10
Vascular access in haemodialysis: strengthening the Achilles' heel. Nat Rev Nephrol (2013) 1.09
Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study. J Vasc Surg (2009) 1.07
Laparoscopic donor nephrectomy vs. open live donor nephrectomy: a quality of life and functional study. Clin Transplant (2005) 1.07
A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant (2005) 1.02
Clinical epidemiology of arteriovenous fistula in 2007. J Nephrol (2007) 1.02
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant (2008) 1.01
Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant (2009) 1.00
Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant (2006) 1.00
Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol (2013) 1.00
A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. J Vasc Access (2012) 0.98
Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation (2011) 0.98
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol (2011) 0.97
Laparoscopic liver resection. J Am Coll Surg (2005) 0.95
Association between donor-specific antibodies and acute rejection and resolution in small bowel and multivisceral transplantation. Transplantation (2011) 0.95
Targeting the ubiquitin+proteasome system in solid tumors. Semin Hematol (2012) 0.95
Hemodynamic wall shear stress profiles influence the magnitude and pattern of stenosis in a pig AV fistula. Kidney Int (2008) 0.95
Gastric bypass in morbidly obese patients with chronic renal failure and kidney transplant. Transplantation (2004) 0.94
Preexisting venous calcification prior to dialysis vascular access surgery. Semin Dial (2012) 0.94
Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant (2005) 0.94
Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum (2004) 0.92
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation. J Am Coll Surg (2010) 0.90
Basic and clinical research in polyomavirus nephropathy. Exp Clin Transplant (2004) 0.90
BKV and JCV large T antigen-specific CD8+ T cell response in HLA A*0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol (2008) 0.90
Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons. J Plast Reconstr Aesthet Surg (2008) 0.90
Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant (2005) 0.90
Desensitization in kidney transplantation: review and future perspectives. Clin Transplant (2014) 0.90
Rare subtypes of BK virus are viable and frequently detected in renal transplant recipients with BK virus-associated nephropathy. Virology (2010) 0.89
Surgical salvage of the autogenous arteriovenous fistula (AVF). J Nephrol (2007) 0.89
Autogenous arteriovenous fistula options. J Nephrol (2007) 0.88
Improving incident fistula rates: a process of care issue. Am J Kidney Dis (2011) 0.88
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation (2012) 0.88
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant (2010) 0.88
Alternative medicine use in dialysis patients: potential for good and bad! Nephron Clin Pract (2006) 0.88
Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival. Transplantation (2015) 0.87
Posttransplant malignancy. Prog Transplant (2004) 0.87
Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation (2004) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid Redox Signal (2014) 0.86
Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit (2007) 0.86
Influence of temporal variation in wall shear stress on intima-media thickening in arteriovenous fistulae. Semin Dial (2012) 0.86
Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int (2015) 0.85
Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access (2014) 0.84
Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation (2007) 0.84
"Venopathy" at work: recasting neointimal hyperplasia in a new light. Transl Res (2010) 0.84
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation (2010) 0.83
Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs (2011) 0.83
A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. Transplantation (2009) 0.83
Vascular mapping techniques: advantages and disadvantages. J Nephrol (2007) 0.83
Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation (2014) 0.83
African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant (2005) 0.83
Is liver transplantation safe and effective in elderly (≥70 years) recipients? A case-controlled analysis. HPB (Oxford) (2014) 0.82